Clinical Trials Browser

INDUSTRY × Tumor-Agnostic × Clear all

NCT04452955 2026-04-22

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Phase 2 Active not recruiting

Neoplasms

NCT05198349 2026-04-22

First in Human Study of M1069 in Advanced Solid Tumors

Phase 1 Terminated

15 enrolled 18 charts

Neoplasm Metastasis

NCT05303532 2026-04-22

ROSY-D

Phase 3 Enrolling by invitation

Neoplasms

NCT05365581 2026-04-22

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1 Recruiting

Adenocarcinoma

NCT05975073 2026-04-22

A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT06555744 2026-04-22

A Study of ZW191 in Participants With Solid Tumors

Phase 1 Active not recruiting

Neoplasms

NCT06614140 2026-04-22

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT06884618 2026-04-21

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

Phase 1 Recruiting

Neoplasms

NCT06997029 2026-04-21

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT05875168 2026-04-20

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07403721 2026-04-20

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis

NCT07258836 2026-04-17

A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

Phase 1 Recruiting

Neoplasms

NCT06959706 2026-04-16

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Carcinoma, Neoplasms

NCT07193511 2026-04-16

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT01481532 2026-04-15

Open Label Clinical Trial of Intravenous Crotoxin Part 3

Phase 1 Not yet recruiting

Neoplasms

NCT04464226 2026-04-15

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Phase 3 Active not recruiting

Neoplasms

NCT05376891 2026-04-15

Met Non Small Cell Cancer Registry (MOMENT)

Neoplasms

NCT06803680 2026-04-15

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis

NCT07005102 2026-04-15

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT07532018 2026-04-15

DXP-106

Phase 1 Recruiting

Neoplasms

NCT04958239 2026-04-14

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1 Active not recruiting

Neoplasms

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis, Neoplasms

NCT05611632 2026-04-14

NHS-Galleri

Phase NA Active not recruiting

142,318 enrolled

Neoplasms

NCT06150157 2026-04-14

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Phase 1 Recruiting

Neoplasms

NCT02908906 2026-04-13

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT03148418 2026-04-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT04606381 2026-04-13

PALOMA

Phase 1 Active not recruiting

Neoplasms

NCT04799054 2026-04-13

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05120596 2026-04-13

First in Human Study of T3P-Y058-739 (T3P)

Phase 1/2 Recruiting

Neoplasms

NCT05155605 2026-04-13

PATHFINDER 2: A Multi-Cancer Early Detection Study

Phase NA Active not recruiting

35,885 enrolled

Neoplasms

NCT05377554 2026-04-13

Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery

Phase 3 Completed

Neoplasms

NCT05862285 2026-04-13

UmbrellaMAX

Phase 3 Recruiting

Neoplasms

NCT05968326 2026-04-13

IMCODE003

Phase 2 Recruiting

Adenocarcinoma

NCT06178614 2026-04-13

A Study of JNJ-87890387 for Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT06941272 2026-04-13

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms

NCT06979596 2026-04-13

OMAHA-015

Phase 2 Recruiting

Neoplasms

NCT07209111 2026-04-13

KANDLELIT-014

Phase 2 Recruiting

Neoplasms

NCT07247110 2026-04-13

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Phase 1 Recruiting

Neoplasms

NCT07335497 2026-04-13

ASCEND

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07524140 2026-04-13

Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT07525141 2026-04-13

A Study of JNJ-1761981 in Participants With Solid Tumors

Phase 1 Not yet recruiting

Neoplasms

NCT05993299 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT06703346 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

Neoplasms

NCT06593522 2026-04-07

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Phase 2 Recruiting

Neoplasms

NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Neoplasms by Site

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT05261399 2026-04-06

SAFFRON

Phase 3 Active not recruiting

Carcinoma, Neoplasm Metastasis

NCT05629234 2026-04-06

ROSY-T

Phase 3 Active not recruiting

Neoplasms

NCT05781555 2026-04-06

Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors

Phase NA Recruiting

Neoplasms